Anzeige
+++Hot Stock!: China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?! China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!+++
EQS-News

Quantum Genesis AI Corp. Issues Statement Regarding OTC Markets Caveat Emptor Designation 12.03.2026, 18:55 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Quantumzyme 0,14 USD +16,67 % Nasdaq OTC

EQS-News: Quantumzyme Corp / Key word(s): Science
Quantum Genesis AI Corp. Issues Statement Regarding OTC Markets Caveat Emptor Designation

12.03.2026 / 18:55 CET/CEST
The issuer is solely responsible for the content of this announcement.


SAN DIEGO, CA - March 12, 2026 (NEWMEDIAWIRE) - Quantum Genesis AI Corp. (OTC: QGAI), a technology company focused on artificial intelligence, computational modeling, and scientific innovation, today issued a statement regarding the Caveat Emptor designation placed on the Company’s securities by OTC Markets Group, Inc. on February 12, 2026.

Since the designation was applied, the Company has made several attempts to communicate with OTC Markets in order to better understand the basis for the designation and to determine what steps may be necessary to address the matter. OTC Markets has indicated that the designation relates to a “public interest concern.” The Company has requested additional clarification and intends to continue cooperating with OTC Markets in order to address the matter.

OTC Markets recently informed the Company that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. Quantum Genesis AI intends to engage with OTC Markets at the earliest available opportunity to initiate that review process.

“We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. “Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”

The Company remains committed to maintaining transparency with its shareholders and the broader investment community. Quantum Genesis AI intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available.

For more information and updates, please visit www.qgaicorp.com and the Company’s profile at www.otcmarkets.com/stock/QGAI.

About Quantum Genesis AI Corp.

Quantum Genesis AI Corp. is focused on advancing next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. The Company’s strategy includes leveraging advanced data-driven tools to support research, discovery, and technology development across emerging sectors while maintaining a commitment to transparency and responsible corporate governance. 

Disclaimer

The information contained in this press release is provided by Quantum Genesis AI Corp. (“Quantum Genesis AI” or the “Company”) for general informational purposes only. This release may include forward-looking statements that reflect the Company’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.

Quantum Genesis AI makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The Company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantum Genesis AI or its affiliates. 

Contact

Naveen Kulkarni
Chief Executive Officer
Quantum Genesis AI Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 225-2902
Email: info@qgaicorp.com
Website: www.qgaicorp.com

View the original release on www.newmediawire.com


News Source: Quantumzyme Corp


12.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Quantumzyme Corp
United States
ISIN: US75955E2054
EQS News ID: 2290778

 
End of News EQS News Service

2290778  12.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer